NewAmsterdam Pharma Company N.V. Overview
Pro stress-test →NewAmsterdam Pharma is a late-stage biopharmaceutical company developing next-generation therapies for cardiometabolic diseases. The company's lead asset, obicetrapib, is an oral CETP inhibitor positioned to address limitations in current LDL cholesterol-lowering treatments, with clinical trials underway across cardiovascular and neurological indications.
Strategic Profile
Pro stress-test →Trading at approximately 35x earnings multiples with significant upside potential, NewAmsterdam has built a focused pipeline around obicetrapib's mechanism. The company demonstrates strong analyst confidence (12 of 12 buy ratings) and trades substantially below peer valuation estimates, positioning it as a differentiated player in the competitive metabolic disease space.
Competitive Landscape
Pro stress-test →NewAmsterdam competes in the cardiometabolic disease therapeutic space against established players developing CETP inhibitors and other LDL-lowering mechanisms. The company's low-dose oral formulation differentiates it from historical CETP inhibitors, positioning obicetrapib as next-generation therapy addressing unmet needs in statin-resistant populations.
Industry Context
NewAmsterdam Pharma Company N.V. operates in Biopharmaceutical / Clinical-Stage Drug Development.
Key facts
Headquarters: Naarden, Netherlands · Employees: 100 · Revenue: $22.5M · Market cap: $3.94B